logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
A

Akira Nakao

Fukuoka University Hospital
H指数:21
被引数:1,347

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Regimen selection for combined immunotherapy in non-small cell lung cancer with PD-L1 < 1%: a multicenter, retrospective study from Japan (SPIRAL-LT1)

PD-L1<1%的非小细胞肺癌联合免疫治疗方案选择：一项来自日本的多中心回顾性研究（SPIRAL-LT1）

Scientific Reports
IF3.9
2026-10-160
OAAI
Daiki Murata; Koichi Azuma; Kenta Murotani; Kazuhiro Ito; Takashi Nomizo; Kazuhiko Yamada; Tatsuya Imabayashi; Kentaro Iwanaga; Kenji Chibana; Takayo Ota; Yuuya Nishii; Akira Nakao; Asuka Okada; Kosuke Hamai; Keiko Tanimura; Kohei Yoshimine; Yosuke Tamura; Ryuichiro Takaki; Yasuhiro Goto; Makoto Hibino; Tomohiro Oba; Toshiyuki Sumi; Hiroyasu Kaneda; Naoya Nishioka; Tadaaki Yamada; Koichi Takayama
Predictive value of TTF-1 expression for stratifying outcomes between dual ICI and chemoimmunotherapy in patients with PD-L1-negative NSCLC

TTF-1表达对PD-L1阴性NSCLC患者接受双重ICI与化疗联合免疫疗法预后分层的预测价值

International Journal of Clinical Oncology
IF2.8
2026-08-040
PRE
Naoya Nishioka; Daiki Murata; Koichi Azuma; Kazuhiro Ito; Takashi Nomizo; Kazuhiko Yamada; Tatsuya Imabayashi; Kentaro Iwanaga; Kenji Chibana; Takayo Ota; Yuuya Nishii; Akira Nakao; Asuka Okada; Kosuke Hamai; Takenori Sakai; Taishi Harada; Keiko Tanimura; Kohei Yoshimine; Yosuke Tamura; Ryuichiro Takaki; Yasuhiro Goto; Makoto Hibino; Tomohiro Oba; Toshiyuki Sumi; Hiroyasu Kaneda; Tadaaki Yamada; Koichi Takayama
Identification of Hidden Cachexia Subgroup in PD-L1-High NSCLC: Comparative Analysis of the AWGC vs. Fearon Criteria

识别PD-L1高表达非小细胞肺癌中隐藏恶病质亚组：AWGC与Fearon标准的比较分析

journal of cachexia, sarcopenia and muscle
IF0
2026-04-120
OAAI
Naoya Nishioka; Hayato Kawachi; Tadaaki Yamada; Motohiro Tamiya; Yoshiki Negi; Yasuhiro Goto; Akira Nakao; Shinsuke Shiotsu; Keiko Tanimura; Takayuki Takeda; Asuka Okada; Taishi Harada; Koji Date; Yusuke Chihara; Isao Hasegawa; Nobuyo Tamiya; Takeo Ogawa; Masahiro Iwasaku; Shinsaku Tokuda; Takashi Kijima; Koichi Takayama
Selecting optimal immunotherapy based on inflammation in stage IV PD-L1 ≥50% gene mutation-negative non-small cell lung cancer: pembrolizumab monotherapy versus combination chemoimmunotherapy

基于炎症选择最优免疫疗法：用于PD-L1 ≥50%基因突变阴性IV期非小细胞肺癌：帕博利珠单抗单药治疗与联合化疗免疫疗法

TRANSLATIONAL LUNG CANCER RESEARCH
IF3.5
2025-11-300
PRE
Kunimatsu, Yusuke; Nishioka, Naoya; Yamada, Tadaaki; Kawachi, Hayato; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Ishida, Masaki; Kijima, Takashi; Takayama, Koichi
Efficacy and Safety of Chemoimmunotherapy in Patients With Advanced Non-small Cell Lung Cancer With Pre-existing Interstitial Pneumonia and Low PD-L1 Expression
ANTICANCER RESEARCH
IF1.7
2025-11-011
PRE
Sasada, Aosa; Kawachi, Hayato; Yamada, Tadaaki; Hata, Tae; Goto, Yasuhiro; Amano, Akihiko; Negi, Yoshiki; Watanabe, Satoshi; Furuya, Naoki; Oba, Tomohiro; Ikoma, Tatsuki; Nakao, Akira; Tanimura, Keiko; Taniguchi, Hirokazu; Yoshimura, Akihiro; Fukui, Tomoya; Murata, Daiki; Kaira, Kyoichi; Shiotsu, Shinsuke; Okada, Asuka; Chihara, Yusuke; Kijima, Takashi; Takayama, Koichi
Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1 < 1 %: A multicenter, retrospective study

免疫检查点抑制剂诱导的间质性肺病（合并与不合并CTLA-4方案）在PD-L1 < 1 %的非小细胞肺癌患者中的研究：一项多中心、回顾性研究

Lung Cancer
IF4.4
2025-09-260
PRE
Daiki Murata; Koichi Azuma; Kenta Murotani; Kazuhiro Ito; Takashi Nomizo; Kazuhiko Yamada; Tatsuya Imabayashi; Kentaro Iwanaga; Kenji Chibana; Takayo Ota; Yuuya Nishii; Akira Nakao; Asuka Okada; Kosuke Hamai; Keiko Tanimura; Kohei Yoshimine; Yosuke Tamura; Ryuichiro Takaki; Yasuhiro Goto; Makoto Hibino; Tomohiro Oba; Toshiyuki Sumi; Hiroyasu Kaneda; Naoya Nishioka; Tadaaki Yamada; Koichi Takayama
Analysis of Poor Prognostic Factors and Treatment Strategies in Platinum-Based Systemic Therapy After EGFR-TKI Failure in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations

携带EGFR突变的患者在EGFR-TKI失败后接受铂类为基础的系统治疗中不良预后因素及治疗策略的分析

Clinical Lung Cancer
IF3.3
2025-07-220
PRE
Tae Hata; Tadaaki Yamada; Naoki Furuya; Hisashi Tanaka; Akihiro Yoshimura; Tomohiro Oba; Makoto Hibino; Takahito Fukuda; Yasuhiro Goto; Akira Nakao; Shinsuke Ogusu; Yuta Okazaki; Taishi Harada; Takayo Ota; Ken Masubuchi; Koji Mikami; Shoki Matsumoto; Ryoichi Honda; Koji Date; Yusuke Chihara
Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study

EGFR突变非小细胞肺癌在EGFR-TKI治疗失败后，化疗免疫疗法批准前后真实世界治疗结局：一项日本队列研究

international journal of oncology
IF2.8
2025-07-220
PRE
Kenji Morimoto; Tadaaki Yamada; Naoki Furuya; Hisashi Tanaka; Akihiro Yoshimura; Tomohiro Oba; Makoto Hibino; Takahito Fukuda; Yasuhiro Goto; Akira Nakao; Shinsuke Ogusu; Yuta Okazaki; Taishi Harada; Takayo Ota; Ken Masubuchi; Koji Mikami; Tae Hata; Shoki Matsumoto; Ryoichi Honda; Koji Date; Yusuke Chihara; Koichi Takayama
Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis

Durvalumab在表皮生长因子受体突变型III期非小细胞肺癌患者接受同步化放疗后的应用：一项日本真实世界数据分析

Lung Cancer
IF4.4
2025-05-270
OA
Toshiya Fujisaki; Eisaku Miyauchi; Gen Kida; Yu Miura; Kana Watanabe; Hironori Ashinuma; Motohiro Tamiya; Hajime Kikuchi; Daisuke Arai; Satoshi Takahashi; Ken Masuda; Ayako Takigami; Yoshiaki Nagai; Taichi Miyawaki; Yukari Tsubata; Akira Nakao; Ken Masubuchi; Kazuhiro Nishiyama; Satoshi Watanabe; Satoshi Morita; Makoto Maemondo
Skin disorder within 30 days is a favorable prognostic factor in patients with lung squamous cell carcinoma treated with necitumumab plus gemcitabine and cisplatin: a sub-analysis of the NINJA study

30天内出现皮肤疾病是接受尼妥珠单抗联合吉西他滨和顺铂治疗的肺鳞状细胞癌患者的有利预后因素：NINJA研究的亚组分析

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
IF4.2
2025-03-150
OA
Fumihiko Kinoshita; Shigeru Tanzawa; Toshihiro Misumi; Hiroshige Yoshioka; Eisaku Miyauchi; Kiichiro Ninomiya; Yasunori Murata; Masafumi Takeshita; Masafumi Yamaguchi; Shunichi Sugawara; Yosuke Kawashima; Kazuki Hashimoto; Masahide Mori; Akihiko Miyanaga; Anna Hayashi; Hisashi Tanaka; Ryoichi Honda; Masafumi Nojiri; Yuki Sato; Ken Yamamoto; Ken Masuda; Toshiyuki Kozuki; Takahisa Kawamura; Takuji Suzuki; Teppei Yamaguchi; Kazuhiro Asada; Satoshi Tetsumoto; Hiroshi Tanaka; Satoshi Watanabe; Yukihiro Umeda; Kakuhiro Yamaguchi; Shoichi Kuyama; Kosuke Tsuruno; Yuki Misumi; Hiroshi Kuraishi; Ken Yoshihara; Akira Nakao; Akihito Kubo; Toshihiko Yokoyama; Kana Watanabe; Nobuhiko Seki
Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study

尼妥珠单抗联合顺铂和吉西他滨治疗在晚期肺鳞状细胞癌患者中诱导低镁血症的临床影响：NINJA研究的亚组分析

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
IF4.2
2025-02-140
OA
Shigeru Tanzawa; Hiroshige Yoshioka; Toshihiro Misumi; Eisaku Miyauchi; Kiichiro Ninomiya; Yasunori Murata; Masafumi Takeshita; Fumihiko Kinoshita; Takatoshi Fujishita; Shunichi Sugawara; Yosuke Kawashima; Kazuki Hashimoto; Masahide Mori; Akihiko Miyanaga; Anna Hayashi; Hisashi Tanaka; Ryoichi Honda; Masafumi Nojiri; Yuki Sato; Akito Hata; Nobuhisa Ishikawa; Toshiyuki Kozuki; Takahisa Kawamura; Go Saito; Teppei Yamaguchi; Kazuhiro Asada; Satoshi Tetsumoto; Hiroshi Tanaka; Satoshi Watanabe; Yukihiro Umeda; Kakuhiro Yamaguchi; Kazuya Nishii; Kosuke Tsuruno; Yuki Misumi; Hiroshi Kuraishi; Ken Yoshihara; Akira Nakao; Akihito Kubo; Toshihiko Yokoyama; Kana Watanabe; Nobuhiko Seki
Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy
ONCOIMMUNOLOGY
IF6.3
2024-12-160
OAAI
Kawachi, Hayato; Yamada, Tadaaki; Tamiya, Motohiro; Negi, Yoshiki; Kijima, Takashi; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Katayama, Yuki; Nishioka, Naoya; Morimoto, Kenji; Iwasaku, Masahiro; Tokuda, Shinsaku; Shimose, Takayuki; Takayama, Koichi
Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non-Small Cell Lung Cancer with PD-L1 Expression Levels of 1%to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective Study

TTF-1表达对PD-L1表达水平为1%至49%的非小细胞肺癌患者预后预测的影响：化疗与化疗免疫治疗的多中心回顾性研究

CANCER RESEARCH AND TREATMENT
IF3.8
2024-10-250
OA
Nishioka, Naoya; Hata, Tae; Yamada, Tadaaki; Goto, Yasuhiro; Amano, Akihiko; Negi, Yoshiki; Watanabe, Satoshi; Furuya, Naoki; Oba, Tomohiro; Ikoma, Tatsuki; Nakao, Akira; Tanimura, Keiko; Taniguchi, Hirokazu; Yoshimura, Akihiro; Fukui, Tomoya; Murata, Daiki; Kaira, Kyoichi; Shiotsu, Shinsuke; Hibino, Makoto; Okada, Asuka; Chihara, Yusuke; Kawachi, Hayato; Kijima, Takashi; Takayama, Koichi
Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort
INVESTIGATIONAL NEW DRUGS
IF2.7
2024-08-210
PRE
Tachibana, Yusuke; Morimoto, Kenji; Yamada, Tadaaki; Kawachi, Hayato; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Katayama, Yuki; Nishioka, Naoya; Iwasaku, Masahiro; Tokuda, Shinsaku; Kijima, Takashi; Takayama, Koichi
Unraveling the influence of TTF-1 expression on immunotherapy outcomes in PD-L1-high non-squamous NSCLC: a retrospective multicenter study
FRONTIERS IN IMMUNOLOGY
IF5.9
2024-07-150
OAAI
Nishioka, Naoya; Kawachi, Hayato; Yamada, Tadaaki; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Masui, Taiki; Sai, Natsuki; Ishida, Masaki; Katayama, Yuki; Morimoto, Kenji; Iwasaku, Masahiro; Tokuda, Shinsaku; Kijima, Takashi; Takayama, Koichi
Association between clinical characteristics and treatment outcome of immune checkpoint inhibitor with or without chemotherapy in elderly non-small cell lung cancer patients with high PD-L1 expression
CANCER RESEARCH
IF16.6
2024-03-220
PRE
Kawachi, Hayato; Takei, Shota; Yamada, Tadaaki; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Kijima, Takashi; Takayama, Koichi
Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50%

免疫检查点抑制剂联合化疗对TPS ≥ 50% 的老年非小细胞肺癌PD-L1预后的影响

FRONTIERS IN IMMUNOLOGY
IF5.9
2024-02-232
OAAI
Takei, Shota; Kawachi, Hayato; Yamada, Tadaaki; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Katayama, Yuki; Nishioka, Naoya; Morimoto, Kenji; Iwasaku, Masahiro; Tokuda, Shinsaku; Kijima, Takashi; Takayama, Koichi

研究方向

暂未获取到该数据
T
Tadaaki Yamada
H 指数:41论文数:563被引数:6,290
Y
Yasuhiro Gotô
H 指数:31论文数:334被引数:3,794
K
Koichi Takayama
H 指数:75论文数:954被引数:1.9万
Y
Yusuke Chihara
H 指数:23论文数:157被引数:3,149
T
Takashi Kijima
H 指数:34论文数:393被引数:5,366
A
Asuka Okada
H 指数:11论文数:105被引数:402
H
Hayato Kawachi
H 指数:16论文数:152被引数:1,117
T
Takayuki Takeda
H 指数:22论文数:196被引数:2,735
K
Keiko Tanimura
H 指数:13论文数:107被引数:1,059
T
Taishi Harada
H 指数:32论文数:221被引数:3,854